Logo image of TECX

TECTONIC THERAPEUTIC INC (TECX) Stock Fundamental Analysis

NASDAQ:TECX - Nasdaq - US8789721086 - Common Stock - Currency: USD

21.45  -0.47 (-2.14%)

Fundamental Rating

2

Taking everything into account, TECX scores 2 out of 10 in our fundamental rating. TECX was compared to 551 industry peers in the Biotechnology industry. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability. TECX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TECX has reported negative net income.
In the past year TECX has reported a negative cash flow from operations.
TECX had negative earnings in each of the past 5 years.
TECX had a negative operating cash flow in each of the past 5 years.
TECX Yearly Net Income VS EBIT VS OCF VS FCFTECX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.63%, TECX is in the better half of the industry, outperforming 78.40% of the companies in the same industry.
Looking at the Return On Equity, with a value of -19.49%, TECX belongs to the top of the industry, outperforming 85.66% of the companies in the same industry.
Industry RankSector Rank
ROA -18.63%
ROE -19.49%
ROIC N/A
ROA(3y)-71.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TECX Yearly ROA, ROE, ROICTECX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

TECX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TECX Yearly Profit, Operating, Gross MarginsTECX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

TECX has more shares outstanding than it did 1 year ago.
TECX has a better debt/assets ratio than last year.
TECX Yearly Shares OutstandingTECX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
TECX Yearly Total Debt VS Total AssetsTECX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TECX has an Altman-Z score of 17.54. This indicates that TECX is financially healthy and has little risk of bankruptcy at the moment.
TECX has a Altman-Z score of 17.54. This is amongst the best in the industry. TECX outperforms 92.56% of its industry peers.
TECX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TECX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.54
ROIC/WACCN/A
WACCN/A
TECX Yearly LT Debt VS Equity VS FCFTECX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 22.92 indicates that TECX has no problem at all paying its short term obligations.
TECX has a better Current ratio (22.92) than 95.64% of its industry peers.
TECX has a Quick Ratio of 22.92. This indicates that TECX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TECX (22.92) is better than 95.64% of its industry peers.
Industry RankSector Rank
Current Ratio 22.92
Quick Ratio 22.92
TECX Yearly Current Assets VS Current LiabilitesTECX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TECX have decreased strongly by -45.91% in the last year.
EPS 1Y (TTM)-45.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TECX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.51% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.17%
EPS Next 2Y19.34%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TECX Yearly EPS VS EstimatesTECX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TECX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TECX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TECX Price Earnings VS Forward Price EarningsTECX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TECX Per share dataTECX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.34%
EPS Next 3Y8.51%

More info and screens

0

5. Dividend

5.1 Amount

TECX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECTONIC THERAPEUTIC INC

NASDAQ:TECX (8/8/2025, 1:16:06 PM)

21.45

-0.47 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners59.47%
Inst Owner Change1.73%
Ins Owners27.31%
Ins Owner Change7.13%
Market Cap400.47M
Analysts83.64
Price Target85.27 (297.53%)
Short Float %16.69%
Short Ratio9.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.58%
Min EPS beat(2)16.54%
Max EPS beat(2)40.61%
EPS beat(4)2
Avg EPS beat(4)-42.28%
Min EPS beat(4)-183.66%
Max EPS beat(4)40.61%
EPS beat(8)4
Avg EPS beat(8)-63.22%
EPS beat(12)5
Avg EPS beat(12)-43.67%
EPS beat(16)7
Avg EPS beat(16)-32.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.03%
PT rev (3m)12.59%
EPS NQ rev (1m)0.17%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)0.62%
EPS NY rev (3m)10.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-7.31
EYN/A
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-3.38
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0
BVpS16.12
TBVpS16.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.63%
ROE -19.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.92
Quick Ratio 22.92
Altman-Z 17.54
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)78.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
EPS Next Y49.17%
EPS Next 2Y19.34%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.46%
EBIT Next 3Y-17.63%
EBIT Next 5YN/A
FCF growth 1Y-44.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.23%
OCF growth 3YN/A
OCF growth 5YN/A